Table of Content

Table of Contents
1.0 Executive Summary
1.1 Research Objectives
1.2 Research Methodology
1.3 Key Findings

2.0 Non-alcoholic Steatohepatitis (NASH): Disease Background and Epidemiology
2.1 NASH is a Chronic Liver Condition
2.2 Dietary and Lifestyle Changes are the Most Effective Treatments for NASH Resolution at Present
2.3 NASH is also Associated with Other Metabolic Diseases
2.4 Type 2 Diabetes Patients May be at a High Risk for NASH/MAFLD

3.0 NASH: A Metabolic Disease
3.1 Influence of Metabolic Factors Requires Widespread Recognition of
3.2 Disease Progression from NASH to Total Liver Failure
3.3 Multiple Factors Influence the Development of NASH and MAFLD
3.4 Multiple Factors Influencing Development of NASH Highlight the Heterogeneity of the Disease

4.0 Market Analysis of NASH Treatments
4.1 NASH Treatments Can Undo the Economic Burden of Patients in Many Countries by Preventing Disease Progression
4.2 Market Forecast of NASH Treatments
4.3 Region-wise Market Share of Potential NASH Treatments
4.4 NASH Market Forecast- Methodology
4.5 Factors Influencing Market Forecast Estimate

5.0 NASH- Disease Diagnosis and its Importance
5.1 There is a Growing Need for Patient Awareness Regarding NASH
5.2 Top Drug Targets that are Being Pursued for the Development of NASH Treatments
5.3 Innovative New Biomarkers for NASH May Pioneer Novel NASH Treatments
5.4 Blood-based Non-invasive NASH biomarkers Do Not Accurately Provide Disease Severity and Fibrosis Stage
5.5 Product Profile of NASH Diagnostic Test- NIS4 IVD

6.0 Product Profiles of Major Late-stage NASH Drugs
6.1 Aramchol
6.2 OCALIVA
6.3 VK2809
6.4 Cenicriviroc
6.5 Elafibranor
6.6 Firsocostat
6.7 Resmetirom
6.8 Tropifexor

7.0 Future Market Trends of NASH Therapies
7.1 NASH Treatments May Enter Multiple Markets as Early as 2021
7.2 NASH Treatment Types will Dictate Future Market Trends
7.3 Pipeline Therapies Could Dominate the Future NASH Market by 2030

8.0 Appendix
8.1 Key Contacts
8.1 Key Contacts (continued)
Legal Disclaimer